![](/img/cover-not-exists.png)
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ladenstein, Ruth, Pötschger, Ulrike, Valteau-Couanet, Dominique, Luksch, Roberto, Castel, Victoria, Yaniv, Isaac, Laureys, Genevieve, Brock, Penelope, Michon, Jean Marie, Owens, Cormac, Trahair, Toby,Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(18)30578-3
Date:
November, 2018
File:
PDF, 347 KB
english, 2018